JP2021511811A5 - - Google Patents

Info

Publication number
JP2021511811A5
JP2021511811A5 JP2020542002A JP2020542002A JP2021511811A5 JP 2021511811 A5 JP2021511811 A5 JP 2021511811A5 JP 2020542002 A JP2020542002 A JP 2020542002A JP 2020542002 A JP2020542002 A JP 2020542002A JP 2021511811 A5 JP2021511811 A5 JP 2021511811A5
Authority
JP
Japan
Prior art keywords
antibody
sequence shown
seq
region
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020542002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511811A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/016139 external-priority patent/WO2019152705A1/en
Publication of JP2021511811A publication Critical patent/JP2021511811A/ja
Publication of JP2021511811A5 publication Critical patent/JP2021511811A5/ja
Priority to JP2023183710A priority Critical patent/JP2024012382A/ja
Priority to JP2025062854A priority patent/JP2025111497A/ja
Pending legal-status Critical Current

Links

JP2020542002A 2018-02-01 2019-01-31 Cd70に特異的な抗体およびその使用 Pending JP2021511811A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023183710A JP2024012382A (ja) 2018-02-01 2023-10-26 Cd70に特異的な抗体およびその使用
JP2025062854A JP2025111497A (ja) 2018-02-01 2025-04-07 Cd70に特異的な抗体およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862625019P 2018-02-01 2018-02-01
US62/625,019 2018-02-01
US201862641873P 2018-03-12 2018-03-12
US62/641,873 2018-03-12
PCT/US2019/016139 WO2019152705A1 (en) 2018-02-01 2019-01-31 Antibodies specific for cd70 and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023183710A Division JP2024012382A (ja) 2018-02-01 2023-10-26 Cd70に特異的な抗体およびその使用

Publications (2)

Publication Number Publication Date
JP2021511811A JP2021511811A (ja) 2021-05-13
JP2021511811A5 true JP2021511811A5 (cg-RX-API-DMAC7.html) 2022-02-04

Family

ID=65494520

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020542002A Pending JP2021511811A (ja) 2018-02-01 2019-01-31 Cd70に特異的な抗体およびその使用
JP2023183710A Pending JP2024012382A (ja) 2018-02-01 2023-10-26 Cd70に特異的な抗体およびその使用
JP2025062854A Withdrawn JP2025111497A (ja) 2018-02-01 2025-04-07 Cd70に特異的な抗体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023183710A Pending JP2024012382A (ja) 2018-02-01 2023-10-26 Cd70に特異的な抗体およびその使用
JP2025062854A Withdrawn JP2025111497A (ja) 2018-02-01 2025-04-07 Cd70に特異的な抗体およびその使用

Country Status (15)

Country Link
US (3) US11377500B2 (cg-RX-API-DMAC7.html)
EP (1) EP3746482A1 (cg-RX-API-DMAC7.html)
JP (3) JP2021511811A (cg-RX-API-DMAC7.html)
KR (1) KR102768098B1 (cg-RX-API-DMAC7.html)
CN (1) CN111936519A (cg-RX-API-DMAC7.html)
AU (1) AU2019215075B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020015641A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090032A1 (cg-RX-API-DMAC7.html)
IL (1) IL276397B1 (cg-RX-API-DMAC7.html)
MX (1) MX2020008183A (cg-RX-API-DMAC7.html)
PE (2) PE20251579A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551153A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006988WA (cg-RX-API-DMAC7.html)
TW (2) TWI878213B (cg-RX-API-DMAC7.html)
WO (1) WO2019152705A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
MX2020008184A (es) 2018-02-01 2020-09-22 Pfizer Receptores de antigeno quimericos dirigidos a cd70.
CN110804099B (zh) * 2019-10-31 2020-06-16 浙江蓝盾药业有限公司 人cd70抗原结合多肽
MX2023000662A (es) * 2020-07-17 2023-02-27 Pfizer Anticuerpos terapeuticos y sus usos.
CA3201499A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
EP4251645A1 (en) 2020-11-25 2023-10-04 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
KR20230169182A (ko) * 2021-04-09 2023-12-15 몰리큘라 파트너스 아게 신규한 DARPin 기반 CD70 인게이저
CN113292652A (zh) * 2021-06-17 2021-08-24 南京蓝盾生物科技有限公司 具有增强的adcc效应的抗cd70抗体及其应用
CN113754769B (zh) * 2021-10-13 2023-06-06 宜明昂科生物医药技术(上海)股份有限公司 靶向cd70的抗体及其制备和用途
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4583999A1 (en) 2022-09-09 2025-07-16 Bristol-Myers Squibb Company Methods of separating chelator
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
EP0644946A4 (en) 1992-06-10 1997-03-12 Us Health VECTOR PARTICLES RESISTANT TO INACTIVATION BY HUMAN SERUM.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
AU6818094A (en) 1993-04-22 1994-11-08 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
WO1995007994A2 (en) 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
HUT75162A (en) 1993-11-16 1997-04-28 Depotech Corp Vesicles with controlled release of actives
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DE69739286D1 (de) 1996-05-06 2009-04-16 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
WO1999018792A1 (en) 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
DK1575517T3 (da) 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
US20080025989A1 (en) * 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7662387B2 (en) * 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20120294863A1 (en) * 2004-10-15 2012-11-22 Seattle Genetics, Inc. Anti-CD70 Antibody and Its Use for the Treatment and Prevention of Cancer and Immune Disorders
WO2006044643A2 (en) 2004-10-15 2006-04-27 Seattle Genetics, Inc. Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en) * 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US7641903B2 (en) * 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US8067546B2 (en) * 2005-04-19 2011-11-29 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
EP1934261B1 (en) 2005-09-26 2014-10-29 Medarex, L.L.C. Human monoclonal antibodies to cd70
US20100150950A1 (en) * 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
WO2010024300A1 (ja) 2008-08-26 2010-03-04 国立大学法人 北海道大学 骨充填型軟骨組織再生誘導剤
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
SG189482A1 (en) 2010-10-27 2013-05-31 Cellectis Method for increasing the efficiency of double-strand break-induced mutagenesis
CA2816379A1 (en) * 2010-10-27 2012-05-03 Baylor College Of Medicine Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
BR112013021562B1 (pt) 2011-03-16 2023-01-10 Argenx Bvba Anticorpos para cd70
AP2014007588A0 (en) * 2011-09-22 2014-04-30 Amgen Inc CD27L antigen binding proteins
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
AU2013312838B2 (en) 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof
SI2997141T1 (sl) 2013-05-13 2023-04-28 Cellectis CD19 specifični himerni antigenski receptor in njegova uporaba
CA2912375C (en) 2013-05-13 2023-03-14 Cellectis Methods for engineering highly active t cell for immunotherapy
JP6608807B2 (ja) 2013-05-29 2019-11-20 セレクティス Rnaガイドcasヌクレアーゼ系を用いることによって免疫療法のためにt細胞を操作するための方法
US10195289B2 (en) 2013-07-31 2019-02-05 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
JP2016531920A (ja) * 2013-09-05 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップAduro Biotech Holdings, Europe B.V. Cd70結合ペプチドおよびそれに関連する方法、プロセスおよび用途
CN104442012A (zh) 2013-10-23 2015-03-25 冯林 一种文件修改喷墨装置
DK3105317T3 (en) 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
ES2743809T3 (es) * 2014-07-31 2020-02-20 Amgen Res Munich Gmbh Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
EP3250602A1 (en) 2015-01-26 2017-12-06 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
DE102015101304B3 (de) 2015-01-29 2016-03-17 Fujitsu Technology Solutions Intellectual Property Gmbh Rackserver für ein Serverrack
HUE057285T2 (hu) 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
TWI700298B (zh) 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向b細胞成熟抗原之嵌合型抗原受體類
TWI717375B (zh) * 2015-07-31 2021-02-01 德商安美基研究(慕尼黑)公司 Cd70及cd3抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
ES2904593T3 (es) * 2016-01-21 2022-04-05 Pfizer Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
EP3583129B1 (en) 2017-02-14 2021-11-03 Kite Pharma, Inc. Cd70 binding molecules and methods of use thereof
MX2020008184A (es) 2018-02-01 2020-09-22 Pfizer Receptores de antigeno quimericos dirigidos a cd70.

Similar Documents

Publication Publication Date Title
TWI821474B (zh) Cd3抗體及其藥物用途
JP7041516B2 (ja) 共通軽鎖を有する二重特異性抗体又は抗体混合物
CN112969476B (zh) 多特异性蛋白分子
JP2021514664A5 (cg-RX-API-DMAC7.html)
JP2022515318A5 (cg-RX-API-DMAC7.html)
JP2020503870A5 (cg-RX-API-DMAC7.html)
JP2021525546A5 (cg-RX-API-DMAC7.html)
RU2019128134A (ru) Антитело против gprc5d и молекула, содержащая антитело
JP2020515235A5 (cg-RX-API-DMAC7.html)
JP2015508280A5 (cg-RX-API-DMAC7.html)
JP2017537620A5 (cg-RX-API-DMAC7.html)
JP2008520186A5 (cg-RX-API-DMAC7.html)
JP2013520984A5 (cg-RX-API-DMAC7.html)
JP2013527761A5 (cg-RX-API-DMAC7.html)
JP2010509931A5 (cg-RX-API-DMAC7.html)
JP2017529838A5 (cg-RX-API-DMAC7.html)
JP2022533538A5 (cg-RX-API-DMAC7.html)
IL273196B2 (en) Claudin6 antibodies and methods of treating cancer
JP2019506155A5 (cg-RX-API-DMAC7.html)
JP2021528047A5 (cg-RX-API-DMAC7.html)
RU2010129045A (ru) Связывающие молекулы к рецептору ох40 человека
JP2016526904A5 (cg-RX-API-DMAC7.html)
RU2014103784A (ru) Антитело, блокирующее agr2, и его применение
JP2022532173A5 (cg-RX-API-DMAC7.html)
HRP20140502T1 (hr) Humanizirana anti-cxcr4 antitijela za lijeäśenje karcinoma